RECURSION PHARMACEUTICALS (RXRX) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for RECURSION PHARMACEUTICALS.

Analyst Coverage

Research analysts who have asked questions during RECURSION PHARMACEUTICALS earnings calls.

Dennis Cho

Jefferies

2 questions for RXRX

Marcel

Not Disclosed

2 questions for RXRX

Alec Stranahan

Bank of America

1 question for RXRX

Also covers: AGIO, ALEC, BTAI +11 more

Alex Straton

Morgan Stanley

1 question for RXRX

Also covers: AEO, ANF, AS +17 more

Brendan Smith

Stifel, Nicolaus & Company, Incorporated

1 question for RXRX

Also covers: ABCL, ABSI, ARWR +19 more

Brendan Smith and Alec Stranahan

Cowen and Company and BofA Securities

1 question for RXRX

Brendan Smith and Sean Lee

Cowen and Company and Morgan Stanley

1 question for RXRX

Dennis Cho and Mani Foroohar

Jefferies and Leerink Partners

1 question for RXRX

Gil Blum and Sean Lee

Needham & Company and Morgan Stanley

1 question for RXRX

Joe Phillips and Jeff

Not Disclosed / Biovantage

1 question for RXRX

Laura

Not Disclosed

1 question for RXRX

Melissa

Not Disclosed

1 question for RXRX

Also covers: ARCO

Multiple Parties

Multiple Financial Institutions

1 question for RXRX

S. Jane

Not Disclosed

1 question for RXRX

Vikram

Morgan Stanley

1 question for RXRX

Also covers: NFLX

Vikram Purohit

Morgan Stanley

1 question for RXRX

Also covers: ABSI, ARGX, ARQT +11 more

Latest news

Recent press releases and 8-K filings for RXRX.

Recursion Pharmaceuticals Discusses CEO Transition, Financial Outlook, and Pipeline Progress

RXRX

CEO Change

Guidance Update

New Projects/Investments

Recursion Pharmaceuticals announced a smooth CEO transition with Najat Khan succeeding Chris Gibson, who moved to Chairman of the Board, bringing a focus on operational discipline and reducing pro forma spend by 35% from 2024 to 2025.
The company projects to end 2025 with $755 million in cash and an expected cash runway extending to 2027, supported by an outcomes-based financial management model.
Recursion has generated over $500 million in cash inflows from partnerships, including recent achievement of four program milestones with Sanofi, validating its platform and providing significant future revenue potential.
Positive data was announced for REC-4881 in FAP, demonstrating a 43% median reduction in polyp burden within three months, and the company is engaging with the FDA on pivotal trial design.

4 days ago

Transcript

Recursion Pharmaceuticals Highlights AI-Driven Platform, Cost Efficiency, and Clinical Progress

RXRX

CEO Change

Guidance Update

New Projects/Investments

Recursion Pharmaceuticals (RXRX) leverages an AI and automation-driven platform, possessing over 45 PB of proprietary data, and has generated over $500 million in cash inflows from partnerships with companies such as Roche, Genentech, and Sanofi.
Following the CEO transition to Najat Khan, the company has implemented operational efficiencies, leading to a 35% reduction in pro forma spend for 2024 (over $200 million) while maintaining strategic objectives.
Positive clinical results were reported for REC-4881 in FAP patients, showing a 43% median reduction in polyp burden within three months, with ongoing discussions with the FDA for pivotal trial design.
Recursion expects to conclude 2025 with $755 million in cash, projecting a cash runway extending to 2027, supported by a new outcomes-based financial management system and strategically structured partnerships.

4 days ago

Transcript

Recursion Pharmaceuticals Discusses AI Strategy, Leadership Transition, and Financial Outlook

RXRX

CEO Change

Guidance Update

New Projects/Investments

Recursion Pharmaceuticals, an AI-native biotech, has generated over 45 petabytes of proprietary data and secured over $500 million in cash inflows from partnerships, including significant milestones recently achieved with Sanofi.
Najat Khan recently assumed the CEO role, bringing a focus on operational discipline and cash management, which has already resulted in a 35% reduction in pro forma spend for the coming year (2025).
The company anticipates ending 2025 with $755 million in cash, extending its financial runway out to 2027, supported by an outcomes-based financial model and pre-funded partnership development.
Recent clinical data for REC-4881 in FAP patients demonstrated a 43% median reduction in polyp burden within three months, a notable improvement compared to existing clinical results.

4 days ago

Transcript

Recursion Provides Business Update at J.P. Morgan Healthcare Conference

RXRX

Guidance Update

New Projects/Investments

Recursion reported $755 million in cash at year-end 2025, providing an expected runway until year-end 2027, with a projected 2026 cash burn of less than $390 million, representing a 35% reduction from 2024 pro forma.
The company achieved its first AI-enabled clinical proof of concept with REC-4881 (FAP program), demonstrating meaningful, rapid, and durable polyp reduction in 75% of patients, and plans to engage the FDA in 1H 2026 to align on a registrational study plan.
Recursion has secured over $500 million in upfront and milestone payments from partnerships, including four milestones with Sanofi and the delivery of six AI-powered maps of biology to Roche Genentech.
The company is focusing on disciplined execution, portfolio prioritization, and leveraging its AI-native platform across biology, chemistry, and clinical development to accelerate drug discovery and development.

7 days ago

Transcript

Recursion Pharmaceuticals Provides Business Update and Financial Outlook

RXRX

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

Recursion Pharmaceuticals (RXRX) reported $755 million in cash at year-end 2025, providing an expected runway through year-end 2027, with an anticipated 2026 cash burn of less than $390 million. The company has also streamlined operations by 35% and expects a 35% reduction in pro forma operating expenses from 2024 to 2026.
The company's AI-native platform has enabled approximately 5 wholly owned clinical development programs and 15 partnered discovery programs, achieving over $500 million in upfront and milestones from collaborations, including the first AI-enabled clinical proof-of-concept with REC-4881 for FAP.
Key upcoming milestones for 2026 include FDA engagement for REC-4881 in 1H 2026, early safety and PK data for REC-1245 in 1H 2026, and go/no-go decisions for REC-7735 and REC-102 in 2H 2026.

7 days ago

Presentation

Recursion Highlights Financial Runway, Clinical Progress, and CEO Transition at J.P. Morgan Healthcare Conference

RXRX

Guidance Update

CEO Change

New Projects/Investments

Recursion announced an expected cash runway until the end of 2027, supported by $755 million in year-end 2025 cash and a projected 2026 cash burn of less than $390 million, representing a 35% reduction from 2024.
The company achieved its first AI-enabled clinical proof of concept with REC-4881, demonstrating meaningful, rapid, and durable polyp reduction in FAP, and plans to engage with the FDA in the first half of 2026 to define a registrational study path.
Recursion has generated over $500 million in upfront and milestones from partnerships, including four milestones with Sanofi and delivering six AI-powered maps of biology with Roche Genentech.
Najat Khan has been appointed as the new CEO.

7 days ago

Transcript

Recursion Pharmaceuticals Updates on Financial Position, Clinical Progress, and Partnerships

RXRX

Guidance Update

New Projects/Investments

Recursion Pharmaceuticals, Inc. reported $755 million in cash, cash equivalents, and restricted cash as of December 31, 2025, providing an expected runway through year-end 2027.
The company anticipates a 2026 cash burn of less than $390 million.
Recursion achieved its first AI-enabled clinical proof-of-concept with REC-4881 for Familial Adenomatous Polyposis (FAP), demonstrating median polyp burden reductions of 43% at Week 13 and 53% at Week 25.
Through partnerships, Recursion has achieved over $500 million in total cash inflows, including specific milestones with Roche and Genentech, and Sanofi.
The company's wholly-owned clinical pipeline includes approximately 5 programs, with several upcoming milestones in 2026 and 2027.

Jan 12, 2026, 1:21 PM

8-K

RXRX Provides Update on REC-4881 Phase 1b/2 Trial in FAP

RXRX

Product Launch

New Projects/Investments

RXRX announced updated safety and efficacy data from its ongoing Phase 1b/2 trial of REC-4881, an allosteric MEK1/2 inhibitor, as monotherapy in Familial Adenomatous Polyposis (FAP), a condition with no approved pharmacotherapy.
The trial demonstrated rapid and durable reductions in polyp burden, with a median reduction of 43% at Week 13 (on-treatment) and 53% at Week 25 (12 weeks off-treatment).
75% of evaluable patients responded by Week 13, and 82% responded after 3 months off-treatment, indicating a sustained biological effect.
Safety data were consistent with MEK1/2 class effects, predominantly Grade 1/2, with low rates of Grade 3 and no Grade 4/5 events.
RXRX plans to engage the FDA in 1H 2026 to define a potential registration path for REC-4881.

Dec 8, 2025, 1:00 PM

Presentation

Recursion Provides Positive Phase 1b/2 TUPELO Study Update for REC-4881

RXRX

New Projects/Investments

Recursion announced positive updated safety and efficacy results from its ongoing Phase 1b/2 TUPELO study for REC-4881 in Familial Adenomatous Polyposis (FAP).
At week 13, 75% of evaluable patients demonstrated a reduction in total polyp burden, with a median reduction of 43%.
The effects were durable, with 82% of patients remaining responders at week 25 (12 weeks post-therapy), showing a median reduction of 53%.
Safety data for REC-4881 showed primarily Grade 1-2 events, low Grade 3 rates, and no Grade 4-5 events observed, consistent with MEK1/2 inhibitor class expectations.
Recursion plans to engage the FDA in the first half of 2026 to discuss a registration path for REC-4881.

Dec 8, 2025, 1:00 PM

Transcript

Recursion (RXRX) Announces Positive Phase 1b/2 TUPELO Study Results for REC-4881 in FAP

RXRX

Recursion (RXRX) announced positive updated safety and efficacy results from its ongoing Phase 1b/2 TUPELO study evaluating REC-4881 for Familial Adenomatous Polyposis (FAP).
The study demonstrated rapid and substantial efficacy, with a median reduction of 43% in polyp burden by week 13, and 75% of patients responding.
The effects were durable, with 82% of patients remaining responders and a median reduction of 53% in polyp burden at week 25, 12 weeks after stopping therapy. This contrasts with a mean annualized increase of 60% in polyp burden observed in untreated FAP patients.
Safety was consistent with the MEK inhibitor class, primarily grade 1-2 events, with a low rate of grade 3 events and no grade 4 or 5 events reported.
Recursion plans to engage the FDA in H1 2026 to discuss a registration path for REC-4881, which was discovered using its AI-driven phenotypic platform.